+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Lung Cancer Genomic Testing Market by Technology (Fluorescence In Situ Hybridization, Microarray, Next Generation Sequencing), Test Type (Liquid Biopsy, Tissue Biopsy), Application, End User - Global Forecast 2025-2030- Product Image
Lung Cancer Genomic Testing Market by Technology (Fluorescence In Situ Hybridization, Microarray, Next Generation Sequencing), Test Type (Liquid Biopsy, Tissue Biopsy), Application, End User - Global Forecast 2025-2030- Product Image
Sale

Lung Cancer Genomic Testing Market by Technology (Fluorescence In Situ Hybridization, Microarray, Next Generation Sequencing), Test Type (Liquid Biopsy, Tissue Biopsy), Application, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5925112
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Lung Cancer Genomic Testing Market is seeing marked evolution as global stakeholders in diagnostics and oncology push for innovations that enhance clinical workflows and outcomes in precision medicine. As advanced molecular techniques become central to disease management, industry leaders face new opportunities and challenges in technology adoption, partnership strategies, and operational efficiency.

Market Snapshot: Lung Cancer Genomic Testing Market Overview

The Lung Cancer Genomic Testing Market grew from USD 1.07 billion in 2024 to USD 1.16 billion in 2025. It is expected to continue growing at a CAGR of 8.35%, reaching USD 1.73 billion by 2030. Market growth is fueled by advances in genomic technologies, a growing emphasis on personalized medicine, and strategic collaboration among global diagnostic and pharmaceutical players. The competitive arena is shaped by continuous innovation, regulatory adaptation, and increasing demand for comprehensive diagnostic solutions across all regions.

Scope & Segmentation

  • Technology Platforms: Fluorescence In Situ Hybridization, Microarray, Next Generation Sequencing (including Targeted Sequencing, Whole Exome Sequencing, Whole Genome Sequencing), Real Time Polymerase Chain Reaction, Sanger Sequencing.
  • Test Types: Liquid Biopsy (Circulating Tumor Cells, Circulating Tumor DNA), Tissue Biopsy (Fine Needle Aspiration, Tissue Section).
  • Applications: Companion Diagnostics, Predictive Testing, Prognostic Testing, Treatment Monitoring.
  • End Users: Academic and Research Institutes, Hospitals and Diagnostic Laboratories, Pharmaceutical and Biotechnology Companies.
  • Regional Coverage: Americas (e.g., United States, Canada, Brazil, Mexico, Argentina), Europe, Middle East & Africa (e.g., United Kingdom, Germany, France, United Arab Emirates, South Africa), Asia-Pacific (e.g., China, India, Japan, Australia, South Korea, Singapore).
  • Key Companies Analyzed: Illumina, Inc.; Thermo Fisher Scientific Inc.; F. Hoffmann-La Roche AG; QIAGEN N.V.; Guardant Health, Inc.; Myriad Genetics, Inc.; Natera, Inc.; BioMérieux S.A.; NeoGenomics Laboratories, Inc.; Foundation Medicine, Inc.

Lung Cancer Genomic Testing Market: Key Takeaways

  • Next generation sequencing dominates technology adoption, driving accurate and rapid mutation profiling essential for guiding therapy decisions.
  • Liquid biopsy innovations support a shift toward minimally invasive, real-time disease monitoring, complementing traditional tissue-based workflows.
  • Strategic collaborations between diagnostics, pharmaceuticals, and academic centers accelerate the translation of genomic insights into clinical applications and companion diagnostics.
  • Regulatory frameworks are evolving to address complex assay standards, expediting approvals while maintaining rigorous quality requirements.
  • Market leaders are investing in automation, AI-driven analytics, and regional manufacturing to enhance scalability and supply chain resilience.
  • Segment differentiation presents targeted opportunities, with end users requiring tailored solutions to meet the specific demands of research, clinical, and commercial environments.

Tariff Impact: Navigating United States Policy Change

The 2025 United States tariffs on diagnostic imports have posed significant supply chain and procurement challenges across the lung cancer genomic testing market. Laboratories and vendors have responded by diversifying suppliers, negotiating long-term contracts, and investing in domestic manufacturing to offset added costs. Pharmaceutical and biotech partners have restructured project timelines and prioritized local production of critical assay components. Strategic stockpiling and decentralized sourcing are helping maintain margin stability and reliability of clinical operations, reflecting the sector’s adaptive resilience.

Methodology & Data Sources

This report is underpinned by extensive primary interviews with laboratory directors, oncology clinicians, and industry supply chain experts. Secondary research integrates data from peer-reviewed journals, regulatory policies, corporate disclosures, and proprietary databases. Quantitative modeling and triangulation ensure accuracy and integrity in capturing segmentation and trend insights.

Why This Report Matters

  • Enables strategic planning for executives seeking to invest in, partner with, or expand within the lung cancer genomic testing ecosystem.
  • Provides actionable intelligence on the impact of evolving technologies, regulatory protocols, and global market segmentation.
  • Facilitates informed decisions by highlighting innovative approaches, operational best practices, and opportunities for cross-sector collaboration.

Conclusion

Senior leadership and decision-makers will find in-depth analysis and practical recommendations to guide their approach in a complex, rapidly advancing sector. The report offers an evidence-based foundation to support market entry, investment, or expansion priorities in lung cancer genomic testing.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of liquid biopsy assays for early detection of actionable lung cancer mutations using blood samples
5.2. Integration of AI-driven bioinformatics platforms for rapid analysis of complex genomic profiles in NSCLC patients
5.3. Adoption of comprehensive next generation sequencing panels to identify rare driver mutations and resistance mechanisms
5.4. Growth of companion diagnostic approvals for targeted therapies in ALK, ROS1, EGFR mutated non small cell lung cancer
5.5. Expansion of decentralized genomic testing services to improve accessibility in remote and underserved patient populations
5.6. Implementation of reimbursement frameworks and value-based pricing models for advanced lung cancer genomic tests
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Lung Cancer Genomic Testing Market, by Technology
8.1. Introduction
8.2. Fluorescence In Situ Hybridization
8.3. Microarray
8.4. Next Generation Sequencing
8.4.1. Targeted Sequencing
8.4.2. Whole Exome Sequencing
8.4.3. Whole Genome Sequencing
8.5. Real Time Polymerase Chain Reaction
8.6. Sanger Sequencing
9. Lung Cancer Genomic Testing Market, by Test Type
9.1. Introduction
9.2. Liquid Biopsy
9.2.1. Circulating Tumor Cells
9.2.2. Circulating Tumor Dna
9.3. Tissue Biopsy
9.3.1. Fine Needle Aspiration
9.3.2. Tissue Section
10. Lung Cancer Genomic Testing Market, by Application
10.1. Introduction
10.2. Companion Diagnostics
10.3. Predictive Testing
10.4. Prognostic Testing
10.5. Treatment Monitoring
11. Lung Cancer Genomic Testing Market, by End User
11.1. Introduction
11.2. Academic And Research Institutes
11.3. Hospitals And Diagnostic Laboratories
11.4. Pharmaceutical And Biotechnology Companies
12. Americas Lung Cancer Genomic Testing Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Lung Cancer Genomic Testing Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Lung Cancer Genomic Testing Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Illumina, Inc.
15.3.2. Thermo Fisher Scientific Inc.
15.3.3. F. Hoffmann-La Roche AG
15.3.4. QIAGEN N.V.
15.3.5. Guardant Health, Inc.
15.3.6. Myriad Genetics, Inc.
15.3.7. Natera, Inc.
15.3.8. BioMérieux S.A.
15.3.9. NeoGenomics Laboratories, Inc.
15.3.10. Foundation Medicine, Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. LUNG CANCER GENOMIC TESTING MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 6. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. LUNG CANCER GENOMIC TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. LUNG CANCER GENOMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. LUNG CANCER GENOMIC TESTING MARKET: RESEARCHAI
FIGURE 24. LUNG CANCER GENOMIC TESTING MARKET: RESEARCHSTATISTICS
FIGURE 25. LUNG CANCER GENOMIC TESTING MARKET: RESEARCHCONTACTS
FIGURE 26. LUNG CANCER GENOMIC TESTING MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. LUNG CANCER GENOMIC TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE SECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE SECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PROGNOSTIC TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PROGNOSTIC TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 97. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 98. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 99. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 100. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 101. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 102. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 103. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
TABLE 104. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2030 (USD MILLION)
TABLE 105. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
TABLE 106. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2030 (USD MILLION)
TABLE 107. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 108. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 109. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 112. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 113. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 114. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 115. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 116. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 117. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
TABLE 118. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2030 (USD MILLION)
TABLE 119. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
TABLE 120. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2030 (USD MILLION)
TABLE 121. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 122. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 123. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 126. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 140. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 170. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 184. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 185. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 186. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 187. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 188. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 189. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
TABLE 190. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2030 (USD MILLION)
TABLE 191. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
TABLE 192. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2030 (USD MILLION)
TABLE 193. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 194. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 195. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 198. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 199. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 200. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 201. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 202. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 203. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
TABLE 204. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2030 (USD MILLION)
TABLE 205. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
TABLE 206. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2030 (USD MILLION)
TABLE 207. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 208. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 209. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 212. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 217. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
TABLE 218. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2030 (USD MILLION)
TABLE 219. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
TABLE 220. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2030 (USD MILLION)
TABLE 221. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 222. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 223. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 224. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 225. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 226. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 227. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 228. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 229. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 230. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 231. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
TABLE 232. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2030 (USD MILLION)
TABLE 233. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
TABLE 234. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2030 (USD MILLION)
TABLE 235. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 236. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 237. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 240. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 241. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 242. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 243. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 244. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 245. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
TABLE 246. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2030 (USD MILLION)
TABLE 247. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
TABLE 248. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2030 (USD MILLION)
TABLE 249. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 250. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 251. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 268. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 270. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 272. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
TABLE 274. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
TABLE 276. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 278. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 282. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 284. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 286. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
TABLE 288. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2030 (USD MILLION)
TABLE 289. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
TABLE 290. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2030 (USD MILLION)
TABLE 291. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 292. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 293. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 294. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 295. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 296. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 297. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 298. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 299. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 300. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 301. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
TABLE 302. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2030 (USD MILLION)
TABLE 303. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
TABLE 304. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2030 (USD MILLION)
TABLE 305. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 306. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 307. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 308. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 309. NETHERLANDS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Lung Cancer Genomic Testing market report include:
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche AG
  • QIAGEN N.V.
  • Guardant Health, Inc.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • BioMérieux S.A.
  • NeoGenomics Laboratories, Inc.
  • Foundation Medicine, Inc.

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.16 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.73 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Predictive Genetics Market by Technology (Microarray, Next Generation Sequencing, Polymerase Chain Reaction), Test Type (Cancer Screening, Carrier Screening, Pharmacogenomics), Application, End User, Product Type - Global Forecast 2025-2030 - Product Image

Predictive Genetics Market by Technology (Microarray, Next Generation Sequencing, Polymerase Chain Reaction), Test Type (Cancer Screening, Carrier Screening, Pharmacogenomics), Application, End User, Product Type - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Gene Fusion Testing Market by Technology (Fluorescence In Situ Hybridization, Immunohistochemistry, Next Generation Sequencing), Sample Type (Blood, Tissue), Application, End User - Global Forecast 2025-2030 - Product Image

Gene Fusion Testing Market by Technology (Fluorescence In Situ Hybridization, Immunohistochemistry, Next Generation Sequencing), Sample Type (Blood, Tissue), Application, End User - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Next Generation Sequencing Kits Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2031F - Product Image

Next Generation Sequencing Kits Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2031F

  • Report
  • 188 Pages
  • Global
From
Rare Disease Genetic Testing Market Size, Share & Trends Analysis Report By Disease (Neurological Disorders), By Technology (Next Generation Sequencing, Array Technology, PCR-based Testing), By Specialty, By End-use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Rare Disease Genetic Testing Market Size, Share & Trends Analysis Report By Disease (Neurological Disorders), By Technology (Next Generation Sequencing, Array Technology, PCR-based Testing), By Specialty, By End-use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 180 Pages
  • Global
From
Genomic Cancer Panel and Profiling Markets 2025-2029 by Cancer, Application, Tissue, and Gene Type with Screening Potential Market Size, Featuring Executive & Consultant Guides - Product Image

Genomic Cancer Panel and Profiling Markets 2025-2029 by Cancer, Application, Tissue, and Gene Type with Screening Potential Market Size, Featuring Executive & Consultant Guides

  • Report
  • 585 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.